Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs – Real World Data Across Three Major World Regions With More Than 400.000 Patients: The CVD-REAL 2 Study
Todos os estudos aqui apresentados podem ser consultados na íntegra no site do American College of Cardiology
http://www.acc.org/education-and-meetings/image-and-slide-gallery
